CAR-T CD30 for Hodgkin’s Lymphoma

Home / CAR-T CD30 for Hodgkin’s Lymphoma

CAR-T CD30 for progressive relapsed/refractory Hodgkin’s lymphoma

Chimeric Antigen Receptor T cell (CAR-T) therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors. TRIAL DATA Phase I Clinical Trial – VIEW PRESS HERE May 22, 2015

Name of StudyCD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
PhaseClinical Trial Phase I IdentifierNCT02259556 - view study online here
Study TypeInterventional
Study DesignEndpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Principal InvestigatorWei Dong Han, MD, PhD
Hospital(s)Chinese PLA General Hospital (PLAGH)